September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Martin Zapata Laguado: KN564 maintain benefit on OS in ccRCC
Jun 2, 2025, 06:19

Martin Zapata Laguado: KN564 maintain benefit on OS in ccRCC

Martin Zapata Laguado, Clinical Oncologist at the National Cancer Institute E.S.E., shared on X:

“ASCO 2025 update data on KN564 maintain benefit on OS, all patients in the trial benefit from Pembrolizumab adjuvant, however we lack more biomarkers perhaps a measure in KIM1 would be outstanding.”